This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

FluMist Quadrivalent

AstraZeneca PLC

Drug Names(s): Fluenz Tetra, MEDI3250, MEDI-3250

Description: MEDI-3250 (quadrivalent influenza vaccine, live attenuated, intranasal) is an intranasally administered, live attenuated quadrivalent influenza vaccine version of FluMist. It is intended for the active immunization of individuals 2 to 49 years of age against influenza disease caused by influenza virus A subtypes and B types.

Deal Structure: MEDI-3250 was originally developed by MedImmune.

In June 2007, AstraZeneca closed its acquisition of MedImmune.

AstraZeneca and Daiichi Sankyo
In September 2015, MedImmune, AstraZeneca's global biologics research and development arm, and Daiichi Sankyo entered into an agreement granting Daiichi Sankyo an exclusive license to develop and commercialise FluMist Quadrivalent in Japan.

Under the terms of the agreement, Daiichi Sankyo will pay AstraZeneca an upfront fee with subsequent development milestones and sales-related payments post launch. Daiichi Sankyo will take on the full responsibility for the future development and commercialisation of FluMist Quadrivalent in Japan and will hold the marketing authorisation; AstraZeneca will supply FluMist Quadrivalent to Daiichi Sankyo.

DRI Capital
On an undisclosed date, DRI Capital purchased royalties relating to the sales of FluMist for influenza. As a result of this transaction, DRI...See full deal structure in Biomedtracker

Partners: Daiichi Sankyo Co., Ltd. DRI Capital Inc.

FluMist Quadrivalent News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug